King's College criteria for paracetamol hepatotoxicity (also searched with possessive and alternate eponym spellings including Kings College criteria and King's College Hospital criteria, ICD-10: K72.0) represent the internationally accepted prognostic staging system utilized to identify patients with paracetamol-induced acute liver failure (ALF) who harbor an exceptionally high risk of mortality without emergency orthotopic liver transplantation (OLT)1. Developed at King's College Hospital in London, these criteria stratify patients based on dynamic laboratory markers of acid-base status, coagulopathy, renal function, and neurological status to guide timely referral and listing for transplantation1.
Etiology & Risk Factors
- Intentional vs. Accidental Overdose: Massive intentional self-poisoning is the predominant etiology leading to fulminant hepatic failure, though staggered therapeutic misadventures (pain management over-supplementation over multiple days) carry a notably high mortality due to delayed presentation and unrecognized toxicity1.
- Enzymatic Inducers: Chronic co-ingestion of cytochrome P450 inducers (such as ethanol, carbamazepine, phenytoin, rifampin, or barbiturates) accelerates the conversion of paracetamol into its toxic intermediate, significantly lowering the threshold for severe hepatotoxicity.
- Depleted Glutathione Reserves: Conditions associated with baseline malnutrition, eating disorders, prolonged fasting, or HIV infection deplete hepatic glutathione stores, impairing detoxification pathways and exacerbating cellular injury.
- Delayed Administration of Antidote: Presentation beyond 8 to 24 hours post-ingestion without prompt initiation of N-acetylcysteine substantially escalates the risk of progressing to grade III or IV hepatic encephalopathy and fulminant hepatic failure.
Pathophysiology
At therapeutic doses, paracetamol is primarily metabolized via hepatic glucuronidation and sulfation into inactive, water-soluble metabolites. A small fraction (approximately 5% to 15%) is oxidized by the cytochrome P450 enzyme system—predominantly CYP2E1, CYP3A4, and CYP1A2—into the reactive, highly electrophilic intermediate metabolite N-acetyl-p-benzoquinone imine (NAPQI)1. Under normal physiological conditions, NAPQI is rapidly detoxified via conjugation with reduced glutathione (GSH) to form nontoxic mercapturic acid and cysteine conjugates, which are subsequently excreted by the kidneys.
In the setting of a massive paracetamol overdose, glucuronidation and sulfation pathways become rapidly saturated. Consequently, a significantly larger proportion of the drug is shunted through the cytochrome P450 pathway, leading to massive overproduction of NAPQI. This surge overwhelms and rapidly depletes intracellular hepatic glutathione reserves (often by more than 70%). Unconjugated NAPQI then binds covalently to cellular and mitochondrial proteins, precipitating mitochondrial dysfunction, adenosine triphosphate (ATP) depletion, generation of reactive oxygen species (ROS), lipid peroxidation, and catastrophic centrilobular (Zone 3) necrosis. The resulting massive destruction of functional hepatocytes triggers systemic inflammatory responses, multi-organ system failure, coagulopathy due to impaired synthesis of vitamin K-dependent clotting factors, and cerebral edema driven by hyperammonemia and cytotoxic brain swelling.
Clinical Presentation & Classic Clinical Signs
- History & Cardinal Symptoms: The clinical course classically unfolds in distinct phases. Phase 1 (0 to 24 hours) often manifests with non-specific symptoms including nausea, vomiting, diaphoresis, pallor, and lethargy, or may remain entirely asymptomatic. Phase 2 (24 to 72 hours) marks the onset of right upper quadrant abdominal pain, hepatic tenderness, and subclinical elevations in aminotransferases as liver injury develops. Phase 3 (72 to 96 hours) represents the peak of hepatotoxicity, characterized by jaundice, coagulopathy, renal failure, encephalopathy, hypoglycemia, and potential cardiovascular collapse. Phase 4 (4 days to 2 weeks) involves either complete clinical recovery or progression to multi-organ failure.
- Physical Examination & Named Clinical Signs: Physical examination reveals icteric sclerae, generalized jaundice, tender hepatomegaly, and asterixis (flapping tremor) as hepatic encephalopathy emerges. Advanced neuro-critical signs include hyperreflexia, decerebrate or decorticate posturing, sluggishly reactive pupils, and signs of intracranial hypertension associated with cerebral edema.
Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)
| Diagnostic Modality / Test | Expected Clinical & Radiological / Laboratory Finding |
|---|---|
| Gold-Standard Investigation | Arterial blood gas (ABG) demonstrating progressive metabolic acidosis (pH less than 7.3 despite fluid resuscitation) and marked elevation of serum lactate, serving as an independent predictor of fatal outcome. |
| Laboratory Panel | Serum paracetamol concentration (plotted on the Rumack-Matthew nomogram if ingestion is acute and timed between 4 and 24 hours), profound elevations in serum ALT and AST (often exceeding 1,000 to 10,000 IU/L), markedly prolonged prothrombin time (PT) with elevated INR, rising serum creatinine and blood urea nitrogen (BUN) indicating acute tubular necrosis or hepatorenal syndrome, and hypoglycemia. |
| Imaging / Radiology (X-ray, US, CT, MRI) | Abdominal ultrasound with Doppler to evaluate hepatic parenchyma echotexture, rule out acute portal vein thrombosis, and assess for structural biliary obstruction. Transcranial Doppler may be utilized to monitor for elevated intracranial pressure in grade III/IV encephalopathy. |
| ECG / Histopathology / Procedural | 12-lead ECG to assess for ischemic changes secondary to hypoperfusion or electrolyte disturbances. Liver biopsy is rarely required in acute overdose but demonstrates extensive centrilobular (Zone 3) necrosis if performed. |
Staging, Classification & Clinical Scoring Systems
| Criterion / Stage / Score Component | Clinical Threshold, Points & Management Implication |
|---|---|
| pH Criterion (Arterial Blood Gas) | Arterial pH less than 7.3 after adequate fluid resuscitation (or arterial lactate greater than 3.0 mmol/L after fluid resuscitation, or greater than 3.5 mmol/L on admission). Strongly indicates need for emergency OLT. |
| Coagulopathy Criterion | Prothrombin time greater than 100 seconds (or INR greater than 6.5) corresponding to severe synthetic liver failure. |
| Renal Criterion | Serum creatinine greater than 3.4 mg/dL (300 µmol/L) in the presence of established oliguria or anuria. |
| Neurological Criterion | Presence of grade III or IV hepatic encephalopathy (disorientation, confusion, somnolence, response only to noxious stimuli, or coma). |
| Combined Triad Requirement | If pH is greater than 7.3, the patient must manifest all three of the following simultaneously to meet King's College criteria: INR greater than 6.5 (or PT greater than 100s), serum creatinine greater than 3.4 mg/dL, and grade III/IV encephalopathy. |
Differential Diagnosis
| Differential Condition | Distinguishing Clinical, Biochemical & Imaging Features |
|---|---|
| Ischemic Hepatitis ("Shock Liver") | Rapid, dramatic rise in transaminases following an episode of severe systemic hypotension or cardiac arrest, with a more rapid normalization profile once perfusion is restored and minimal synthetic dysfunction compared to paracetamol toxicity. |
| Acute Viral Hepatitis (HAV, HBV, HEV) | Serological testing confirms acute infection (positive anti-HAV IgM, HBsAg, anti-HBc IgM, or anti-HEV IgM); history typically lacks a significant paracetamol ingestion timeline. |
| Autoimmune Hepatitis | Marked elevation of immunoglobulin G (IgG), positive circulating autoantibodies (ANA, SMA, LKM-1), and interface hepatitis on histological examination. |
| Wilson Disease (Fulminant Presentation) | Kayser-Fleischer rings on slit-lamp examination, Coombs-negative hemolytic anemia, low serum ceruloplasmin, and a characteristically low alkaline phosphatase to total bilirubin ratio. |
Management & Treatment Protocol
- Initial Stabilization & Resuscitation: Secure airway, breathing, and circulation (ABCs). Institute continuous hemodynamic and neurological monitoring in an intensive care unit (ICU). Correct severe hypoglycemia with intravenous 10% or 50% dextrose infusions and manage fluid status judiciously to avoid exacerbating cerebral edema while maintaining adequate renal perfusion.
- First-Line Medical / Pharmacological Therapy (with exact adult dosing): Administer intravenous N-acetylcysteine (NAC) immediately. Standard three-bag IV NAC protocol for adults:
- Bag 1: 150 mg/kg in 200 mL of 5% Dextrose infused intravenously over 15 minutes.
- Bag 2: 50 mg/kg in 500 mL of 5% Dextrose infused intravenously over 4 hours.
- Bag 3: 100 mg/kg in 1000 mL of 5% Dextrose infused intravenously over 16 hours.
- Surgical / Interventional Indications: Immediate transplant center evaluation and listing for emergency orthotopic liver transplantation when King's College criteria are fulfilled. Supportive modalities such as continuous renal replacement therapy (CRRT) and targeted temperature management for intracranial hypertension serve as critical bridges to transplantation.
Complications & Prognosis
- Key acute complications include cerebral edema leading to uncal herniation, hepatorenal syndrome requiring renal replacement therapy, severe coagulopathy complicated by gastrointestinal or intracranial hemorrhage, refractory metabolic acidosis, recurrent hypoglycemia, and sepsis secondary to immunocompromise.
- Patients who do not meet transplant criteria and receive timely N-acetylcysteine therapy exhibit a high rate of spontaneous hepatic regeneration and full recovery. Conversely, untreated patients who meet the King's College criteria carry a mortality rate exceeding 80% without emergency liver transplantation. Prognostic evaluation must be continuous, as encephalopathy and acidosis can progress rapidly within hours of presentation.